BBOT logo

BRIDGEBIO ONCOLOGY THERAPEUT

BBOTNASDAQ
πŸ† #3509 by market capEarnings Nov 18US Equity
$2.79β–² $0.10 (+3.91%)
Pre-market Β· at close
πŸ””
Track BBOT
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 3.9%
7dβ–Ό 1.4%
14dβ–Ό 5.3%
30dβ–Ό 28.8%
ytdβ–Ό 77.6%
1yβ–Ό 75.9%
🏦Market Cap
$224M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$2.67 – $2.85
52-Week Range
$2.51 – $14.87
Volume (shares)
26,756
Avg Volume (shares)
β€”
Shares Outstanding
80.2M
Next Earnings
2026-11-18

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-3.04
Dividend Yield
β€”
Dilution (1yr)
+436894.1%
BBOT logo

BRIDGEBIO ONCOLOGY THERAPEUT

BBOT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$146Mβ–² +80.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$115Mβ–² +14890.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
80.0Mβ–² +436894.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$371Mβ–² +$369M YoY
StockOtter Β· stockotter.space

About BRIDGEBIO ONCOLOGY THERAPEUT

BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3KΞ±, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
17 analysts
Strong Buy6
Buy10
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.